Priority Review granted for CUTX-101 could expedite its path to market, potentially becoming the first FDA-approved treatment for Menkes disease. Cyprium is eligible to receive up to $129 million in ...
A Prescription Drug User Fee Act target date of June 30, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results